tetano
Editor, Senior Moderator
BMC Infect Dis
. 2024 Sep 27;24(1):1049.
doi: 10.1186/s12879-024-09861-5. Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants
Mathieu Chalouni[SUP] 1 [/SUP], Paul Loubet[SUP] 2 [/SUP], Edouard Lhomme[SUP] 1 3 4 [/SUP], Laetitia Ninove[SUP] 5 [/SUP], Benoit Barrou[SUP] 6 [/SUP], Jean-Yves Blay[SUP] 7 [/SUP], Maryvonne Hourmant[SUP] 8 [/SUP], Jérome de Seze[SUP] 9 [/SUP], Martine Laville[SUP] 10 11 [/SUP], Bruno Laviolle[SUP] 12 [/SUP], Jean-Daniel Lelièvre[SUP] 13 [/SUP], Jacques Morel[SUP] 14 [/SUP], Stéphanie Nguyen Quoc[SUP] 15 [/SUP], Jean-Philippe Spano[SUP] 16 [/SUP], Benjamin Terrier[SUP] 17 [/SUP], Anne Thiebaut[SUP] 18 [/SUP], Jean-Francois Viallard[SUP] 19 [/SUP], François Vrtovsnik[SUP] 20 [/SUP], Sophie Circosta[SUP] 21 [/SUP], Aude Barquin[SUP] 1 [/SUP], Mariam Gharib[SUP] 22 [/SUP], Eric Tartour[SUP] 23 [/SUP], Béatrice Parfait[SUP] 24 [/SUP], Rodolphe Thiébaut[SUP] 1 3 4 [/SUP], Laurence Meyer[SUP] 25 [/SUP], Xavier de Lamballerie[SUP] 5 [/SUP], Odile Launay[SUP] 2 26 [/SUP], Linda Wittkop[SUP] 27 28 29 [/SUP]; ANRS0001S COV-POPART study group
Affiliations
Background: We assessed the prognostic value of serological humoral markers measured one month after the last dose of the primary COVID-19 vaccine course for predicting the risk of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 infection over the following six months in specific populations.
Methods: ANRS0001SCOV-POPART is a French nationwide multicenter prospective observational cohort study assessing the immune response to Covid-19 vaccines routinely administered to 11 subgroups of patients with chronic disease and a control group. Participants from the ANRS0001S COV-POPART were included if they received at least two doses of Covid-19 vaccine for the primary vaccine course, had measurements of anti-Spike, anti-receptor binding domain (RBD) IgG-specific or neutralizing antibodies one month after the end of the primary vaccine course, without being infected by SARS-CoV-2 before the measurement. SARS-CoV-2 infections defined by a positive PCR/antigenic test or seroconversion to detectable anti nucleocapsid antibodies were evaluated until the first COVID-19 booster injection. Cox proportional hazards models taking into account interval-censored data were implemented to estimate the association between each antibody level and the risk of SARS-CoV-2 infection. Predictive performances were evaluated by the area under the receiving operating characteristic curve (AUROC).
Results: Two thousand five hundred seventy adults from a specific population and 1,123 from the control group were included. The cumulative probabilities of SARS-CoV-2 infections at five months after serological measurement were 6.0% 95% confidence interval: [5.0; 7.9] and 10.1% 95% confidence interval: [8.3; 11.9], respectively. Higher levels of anti-Spike IgG antibody were associated with a lower risk of SARS-CoV-2 infections in the control group, but not in the specific populations. Among the specific populations, AUROC were 74.5%, 74.9%, and 72.4% for anti-Spike IgG, anti-RBD IgG, and neutralizing antibodies, respectively. AUROC were superior in the specific populations, 82.0%, 81.2%, and 81.4% for anti-Spike IgG, anti-RBD IgG, and neutralizing antibodies, respectively.
Conclusions: Vaccine-induced antibody response after the primary course of Covid-19 infection only moderately discriminated between participants developing a SARS-CoV-2 infection during the Omicron wave.
Trial registration: NCT04824651 (first posted: 2021-04-01).
Keywords: Prediction; SARS-CoV-2; Specific populations; Vaccine.
. 2024 Sep 27;24(1):1049.
doi: 10.1186/s12879-024-09861-5. Association between humoral serological markers levels and risk of SARS-CoV-2 infection after the primary COVID-19 vaccine course among ANRS0001S COV-POPART cohort participants
Mathieu Chalouni[SUP] 1 [/SUP], Paul Loubet[SUP] 2 [/SUP], Edouard Lhomme[SUP] 1 3 4 [/SUP], Laetitia Ninove[SUP] 5 [/SUP], Benoit Barrou[SUP] 6 [/SUP], Jean-Yves Blay[SUP] 7 [/SUP], Maryvonne Hourmant[SUP] 8 [/SUP], Jérome de Seze[SUP] 9 [/SUP], Martine Laville[SUP] 10 11 [/SUP], Bruno Laviolle[SUP] 12 [/SUP], Jean-Daniel Lelièvre[SUP] 13 [/SUP], Jacques Morel[SUP] 14 [/SUP], Stéphanie Nguyen Quoc[SUP] 15 [/SUP], Jean-Philippe Spano[SUP] 16 [/SUP], Benjamin Terrier[SUP] 17 [/SUP], Anne Thiebaut[SUP] 18 [/SUP], Jean-Francois Viallard[SUP] 19 [/SUP], François Vrtovsnik[SUP] 20 [/SUP], Sophie Circosta[SUP] 21 [/SUP], Aude Barquin[SUP] 1 [/SUP], Mariam Gharib[SUP] 22 [/SUP], Eric Tartour[SUP] 23 [/SUP], Béatrice Parfait[SUP] 24 [/SUP], Rodolphe Thiébaut[SUP] 1 3 4 [/SUP], Laurence Meyer[SUP] 25 [/SUP], Xavier de Lamballerie[SUP] 5 [/SUP], Odile Launay[SUP] 2 26 [/SUP], Linda Wittkop[SUP] 27 28 29 [/SUP]; ANRS0001S COV-POPART study group
Affiliations
- PMID: 39333909
- PMCID: PMC11429529
- DOI: 10.1186/s12879-024-09861-5
Background: We assessed the prognostic value of serological humoral markers measured one month after the last dose of the primary COVID-19 vaccine course for predicting the risk of severe acute respiratory syndrome coronavirus 2 SARS-CoV-2 infection over the following six months in specific populations.
Methods: ANRS0001SCOV-POPART is a French nationwide multicenter prospective observational cohort study assessing the immune response to Covid-19 vaccines routinely administered to 11 subgroups of patients with chronic disease and a control group. Participants from the ANRS0001S COV-POPART were included if they received at least two doses of Covid-19 vaccine for the primary vaccine course, had measurements of anti-Spike, anti-receptor binding domain (RBD) IgG-specific or neutralizing antibodies one month after the end of the primary vaccine course, without being infected by SARS-CoV-2 before the measurement. SARS-CoV-2 infections defined by a positive PCR/antigenic test or seroconversion to detectable anti nucleocapsid antibodies were evaluated until the first COVID-19 booster injection. Cox proportional hazards models taking into account interval-censored data were implemented to estimate the association between each antibody level and the risk of SARS-CoV-2 infection. Predictive performances were evaluated by the area under the receiving operating characteristic curve (AUROC).
Results: Two thousand five hundred seventy adults from a specific population and 1,123 from the control group were included. The cumulative probabilities of SARS-CoV-2 infections at five months after serological measurement were 6.0% 95% confidence interval: [5.0; 7.9] and 10.1% 95% confidence interval: [8.3; 11.9], respectively. Higher levels of anti-Spike IgG antibody were associated with a lower risk of SARS-CoV-2 infections in the control group, but not in the specific populations. Among the specific populations, AUROC were 74.5%, 74.9%, and 72.4% for anti-Spike IgG, anti-RBD IgG, and neutralizing antibodies, respectively. AUROC were superior in the specific populations, 82.0%, 81.2%, and 81.4% for anti-Spike IgG, anti-RBD IgG, and neutralizing antibodies, respectively.
Conclusions: Vaccine-induced antibody response after the primary course of Covid-19 infection only moderately discriminated between participants developing a SARS-CoV-2 infection during the Omicron wave.
Trial registration: NCT04824651 (first posted: 2021-04-01).
Keywords: Prediction; SARS-CoV-2; Specific populations; Vaccine.